Welcome to our dedicated page for Stryker news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker stock.
Stryker Corporation reports developments as a global medical technology company serving MedSurg, Neurotechnology and Orthopaedics markets. Company news commonly covers operating results, organic sales trends, segment performance, dividends, shareholder-meeting activity and executive finance or investor-relations appointments.
Stryker updates also address portfolio expansion across medical devices, implants, instruments, operating-room equipment, neurotechnology and vascular solutions. Recent corporate activity includes the completed acquisition of Amplitude Vascular Systems, adding an intravascular lithotripsy platform for peripheral arterial disease to Stryker's peripheral vascular portfolio.
Stryker (SYK) is launching Prophecy® Surgical Planning for its Incompass™ Total Ankle System and introducing Hoffmann® LRF smartHEX™ at the 2026 AOFAS Annual Meeting in Seattle.
Prophecy Surgical Planning, which has supported patient-specific planning in more than 100,000 ankle cases over 14 years, now gives Incompass users 3D visualization plus resect-through and pin-through fixation options in a single platform. Hoffmann LRF smartHEX expands the limb reconstruction portfolio with new rings, struts and frame components, alongside a mobile app and updated planning software designed to enhance frame versatility and support connected care between surgeons and patients.
Stryker (SYK) will participate in the 2026 Wells Fargo Healthcare Conference on Tuesday, September 8, 2026, at Encore Boston Harbor.
Vice President and CFO Preston Wells and Vice President, Investor Relations Nick Mead will join a fireside chat at 10:15 a.m. Eastern time. A live audio webcast and replay will be available via Stryker's Events & Presentations webpage.
Stryker (NYSE: SYK) announced the first successful surgical use of its FDA De Novo authorized SportSuite Vision application on Apple Vision Pro during a hip arthroscopy at Duke Health, a leading academic medical center, on September 1, 2026.
SportSuite Vision, authorized on July 17, is the first application cleared by the FDA for intraoperative use with Apple Vision Pro. The system brings arthroscopic video, HipCheck, HipMap and CT imaging into a customizable spatial computing environment, enabling surgeons to view physical objects alongside multiple digital data streams within one ergonomic field of view. According to Stryker, this configuration can reduce reliance on traditional monitors and support more streamlined, ergonomic operating room workflows during arthroscopic procedures.
Stryker (NYSE:SYK) has signed a definitive agreement to acquire ZuriMED, a privately held developer of the commercialized FiberLocker System, a soft tissue augmentation technology for rotator cuff repair. The system is designed to provide a novel rotator cuff augmentation approach with increased biomechanical strength and to reduce a key clinical failure mode in these procedures.
According to Stryker, the deal is intended to strengthen its shoulder portfolio and expand support for shoulder specialists across sports medicine and arthroplasty, particularly in rotator cuff augmentation, described as one of the fastest‑growing areas in sports medicine and a significant opportunity in shoulder care. The transaction is subject to customary closing conditions, and Stryker and ZuriMED will operate as separate entities until closing.
Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference/b) on at Encore Boston Harbor. CFO Preston Wells and VP Investor Relations Nick Mead will join a fireside chat at 2:15 p.m. Eastern time, accessible via live audio webcast and replay on Stryker’s Events & Presentations page.
Providence Medical Technology appointed Lane Major as President & Chief Executive Officer, effective August 6, 2026, and added him to the Board of Directors. The company highlights strong commercial momentum for its CORUS tissue-sparing fusion platform across cervical and lumbar markets, including navigated solutions that integrate with leading surgical navigation systems.
Major brings over 25 years of spine and medical device leadership, including co-founding K2M, guiding it through a 2014 IPO (NASDAQ: KTWO) and a $1.4 billion acquisition by Stryker (NYSE: SYK). At Stryker, he led the Global Spine Business, overseeing roughly $2 billion in investments across more than 40 countries. According to Providence, its TSF platform is supported by Level 1 clinical data, which Major is expected to help further scale.
Stryker (NYSE:SYK) announced that its Board of Directors declared a quarterly dividend of $0.88 per share, payable on July 31, 2026 to shareholders of record as of the close of business on June 30, 2026. The dividend represents a 4.8% increase versus the prior year and is unchanged from the previous quarter, indicating continued cash returns to shareholders.
Stryker (NYSE:SYK) reported second quarter 2026 net sales of $6.6 billion, up 9.4% as reported and 9.0% in constant currency, with organic net sales up 9.0%. MedSurg and Neurotechnology sales rose 9.7% to $3.6 billion, and Orthopaedics sales grew 9.1% to $3.0 billion.
Reported operating income margin was 25.2% and adjusted operating income margin(1) increased 170 bps to 27.4%. Reported EPS increased to $3.30, while adjusted EPS(1) rose 17.9% to $3.69. Net earnings were $1.3 billion, up 44.3%. Operating cash flow for the first half of 2026 was $1.8 billion, compared with $1.4 billion in 2025.
For full year 2026, Stryker now expects organic net sales growth(2) of 8.3%–9.3% and adjusted EPS(2) of $14.95–$15.10, including a modestly positive pricing impact and a slightly favorable expected foreign exchange effect if rates remain near current levels.
Stryker (NYSE: SYK) announced the U.S. commercial launch of Mako RPS (Robotic Power System) for total knee replacement on July 16, 2026. The system debuts the Mako Handheld Robotics platform, extending the Mako portfolio beyond robotic-arm assisted surgery into a new orthopaedic robotics category.
Mako RPS combines intraoperative planning with a robotically enabled saw and Stryker’s patented active adjustment technology, designed to respond to surgeons’ hand movements and help maintain alignment with the surgical plan. It is compatible with Stryker’s Triathlon Total Knee System and built to work with the Q Guidance System, expanding Stryker’s enabling technologies ecosystem.
Stryker (NYSE: SYK) will host a live webcast at 4:30 p.m. ET on Thursday, July 30, 2026 to discuss its second quarter 2026 financial results.
An accompanying earnings press release will be issued at approximately 4:05 p.m. ET, with both webcast and archive available on Stryker’s website.